Seagen statement on outcome of daiichi sankyo arbitration

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today issued a statement regarding the outcome of the arbitration with daiichi sankyo co. ltd. (“daiichi sankyo”) relating to the parties' 2008 collaboration agreement for the use of seagen's antibody-drug conjugate (adc) technology. the arbitrator ruled in favor of daiichi sankyo, citing statute of limitations and disagreement with seagen on the interpretation of the contract. “while we are disappointed with the arbitration decision,
SGEN Ratings Summary
SGEN Quant Ranking